+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Liver And Kidney Disorders Drugs Market Research Reports

Non-Structural Protein 5 Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Non-Structural Protein 5 Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
Farnesoid X Receptor (FXR) Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Farnesoid X Receptor (FXR) Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Lupus Nephritis - Epidemiology Forecast - 2032 - Product Thumbnail Image

Lupus Nephritis - Epidemiology Forecast - 2032

  • Report
  • January 2024
  • 84 Pages
  • Global
From
From
Nephrotic Syndrome - Epidemiology Forecast- 2034 - Product Thumbnail Image

Nephrotic Syndrome - Epidemiology Forecast- 2034

  • Report
  • January 2024
  • 143 Pages
  • Global
From
From
OXLUMO Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

OXLUMO Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • July 2023
  • 30 Pages
  • Global
From
From
From
From
From
From
From
From
From
Loading Indicator

The Liver and Kidney Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs to treat diseases and disorders of the liver and kidneys. These drugs are used to treat a variety of conditions, including hepatitis, cirrhosis, kidney failure, and other kidney-related diseases. The market is highly competitive, with many companies vying for market share. The market is driven by the increasing prevalence of liver and kidney diseases, as well as the development of new treatments and technologies. Additionally, the rising demand for better treatments and the increasing availability of generic drugs are also contributing to the growth of the market. Some of the major companies in the Liver and Kidney Disorders Drugs market include Pfizer, Merck, Novartis, Sanofi, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, and AbbVie. These companies are engaged in the development and production of drugs to treat liver and kidney diseases. Show Less Read more